drugset / Trial / NCT00126373

A Trial of Wellbutrin for Crohn's Disease

NCT00126373

Phase 2/3 Completed 1 enrolled Altschuler, Eric, M.D. GlaxoSmithKline · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators are testing the hypothesis that Wellbutrin (bupropion) can give a clinical remission in Crohn's disease.

Timeline

Start
2005-05
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg
Subject Bupropion Small molecule 300 mg

Indications